498 related articles for article (PubMed ID: 30287870)
1. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
[TBL] [Abstract][Full Text] [Related]
2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
3. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
Front Neurol; 2020; 11():608. PubMed ID: 32765393
[No Abstract] [Full Text] [Related]
4. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
5. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
6. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
7. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
Neurology; 2004 Nov; 63(9):1586-90. PubMed ID: 15534240
[TBL] [Abstract][Full Text] [Related]
9. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis.
Madeddu R; Farace C; Tolu P; Solinas G; Asara Y; Sotgiu MA; Delogu LG; Prados JC; Sotgiu S; Montella A
Neurol Sci; 2013 Feb; 34(2):181-6. PubMed ID: 22362332
[TBL] [Abstract][Full Text] [Related]
10. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
Lee EJ; Lim YM; Kim S; Choi L; Kim H; Kim K; Kim HW; Lee JS; Kim KK
Ann Clin Transl Neurol; 2020 Jun; 7(6):992-1001. PubMed ID: 32495489
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
[TBL] [Abstract][Full Text] [Related]
12. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
[TBL] [Abstract][Full Text] [Related]
13. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
[TBL] [Abstract][Full Text] [Related]
14. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
[TBL] [Abstract][Full Text] [Related]
15. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
[TBL] [Abstract][Full Text] [Related]
16. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
[TBL] [Abstract][Full Text] [Related]
17. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
Abdelhak A; Hottenrott T; Morenas-Rodríguez E; Suárez-Calvet M; Zettl UK; Haass C; Meuth SG; Rauer S; Otto M; Tumani H; Huss A
Front Neurol; 2019; 10():280. PubMed ID: 30972011
[No Abstract] [Full Text] [Related]
18. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
[TBL] [Abstract][Full Text] [Related]
19. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity.
Ayrignac X; Le Bars E; Duflos C; Hirtz C; Maleska Maceski A; Carra-Dallière C; Charif M; Pinna F; Prin P; Menjot de Champfleur N; Deverdun J; Kober T; Marechal B; Fartaria MJ; Corredor Jerez R; Labauge P; Lehmann S
Sci Rep; 2020 Jul; 10(1):10923. PubMed ID: 32616916
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.
Malmeström C; Haghighi S; Rosengren L; Andersen O; Lycke J
Neurology; 2003 Dec; 61(12):1720-5. PubMed ID: 14694036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
